HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia
Figure 1
Cell proliferation and survival after treatment with epigenetic agents in combination with conventional treatment. NB4 and HL60 cells and APL patient promyelocytes were treated with 1 μM Retinoic acid (RA), 2 nM or 8 nM Idarubicin (IDA2 or IDA8), 0.5 μM 3-Deazaneplanocin A (D), and 0.2 μM Belinostat (B) in different combinations; C: untreated cells. (a) Treated cell proliferation and survival were analysed by trypan blue exclusion test. Results are mean ± S.D. (n = 3); P ≤ 0.05, calculated by Student's t-test to determine the significance of difference between groups of treated and untreated samples at the same incubation time. (b) Treated NB4 cell apoptosis was evaluated by staining with Annexin V and Propidium Iodide after 72 hours of treatment. (c) Caspase-3 activation was assessed by immunoblot analysis. (d) Metabolic changes in treated NB4 cells were measured using Agilent Seahorse XF Cell Energy Phenotype Test Kit. OCR: oxygen consumption rate (demonstrates cells mitochondrial respiration); ECAR: extracellular acidification rate (demonstrates rate of glycolysis of the cells); results are mean ± S.D. (n = 2).